A multi-institutional, retrospective, translational study of the relationship between histological immune-related signatures and clinical benefit of paclitaxel + bevacizumab therapy in HER2-negative advanced breast cancer
Not Applicable
- Conditions
- HER2-negative advanced breast cancer
- Registration Number
- JPRN-UMIN000041493
- Lead Sponsor
- The Mt.Fuji Foundation for Healthcare Innovation and Cluster Development Pharma Valley Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 156
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Expression-status of immune-related signatures in primary site 2.Relationships between overall survival (OS)/time-to-treatment failure (TTF) and expression status of immune-related signatures in primary site
- Secondary Outcome Measures
Name Time Method 1.Relationships between overall survival (OS)/time-to-treatment failure (TTF) and expression-status of immune-related signatures in metastatic site 2.Relationships between peripheral immune-related markers/nutritional markers and expression-status of immune-related signatures in metastatic site 3.Changes in markers of epithelial-mesenchymal transition between primary site and metastatic site 4.Relationships between peripheral immune-related markers/nutritional markers and clinical efficacy